ArticleACS omega2024
Fullerene-Based Heterojunctions for Non-Selective Absorption Transparent Solar Cells.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transparent photovoltaic (TPV) devices have great potential to be applied as smart windows in construction and agriculture fields. TPVs with an average visible transmission (AVT) exceeding 50% are among the strong candidates to build lighting windows since the champion efficiency has already exceeded 10%. However, it is still a challenge in TPVs that semiconductors are generally expensive and transparency is difficult to further enhance, particularly for device AVT exceeding 70%. In this work, we develop a set of fullerene-based heterojunctions to harvest the light. By utilizing the low-cost fullerene as the light-absorbing material and combining it with the transparent electrode, the fabricated TPV device can achieve an AVT of 72.1% with a PCE exceeding 1%. Notably, the device with an AVT of 82% is also successfully demonstrated. This study provides an effective approach for building low-cost and efficient TPV devices.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.